GlobeNewswire Inc.··NaTempest Advances CAR-T Program With Manufacturing Deal Ahead of 2026 FDA Filing
Tempest Therapeutics partners with Cincinnati Children's for TPST-2003 manufacturing, targeting U.S. registrational study launch in 2026 following strong interim trial results.
TPSTclinical trialmultiple myeloma